ArticlePloS one2015
MicroRNAs 9 and 370 Association with Biochemical Markers in T2D and CAD Complication of T2D.
Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Common miRNAs, Genes, and Regulatory Pathways in Alzheimer's Disease and Type 2 Diabetes Mellitus: An Integrative Analysis of Systematic Reviews, Bioinformatics and Data Mining.Journal of neurochemistry · 2025Pooled it
- Insights for lncH19, miR-9, and miR-146a expression levels and their cross-talk with pro-inflammatory cytokines, copeptin, and neopterin profile in type 1 diabetic cardiomyopathy.Molecular biology reports · 2025Article
- Mechanistic insight into the role of cardiac-enriched microRNAs in diabetic heart injury.American journal of physiology. Heart and circulatory physiology · 2025Review
- Identification of plasma miR-4505, miR-4743-5p and miR-4750-3p as novel diagnostic biomarkers for coronary artery disease in patients with type 2 diabetes mellitus: a case-control study.Cardiovascular diabetology · 2024Article
- MiR-9-3 hypermethylation is associated with stages of diabetic retinopathy.Journal of diabetes and metabolic disorders · 2024Article
- Conserved miR-370-3p/BMP-7 axis regulates the phenotypic change of human vascular smooth muscle cells.Scientific reports · 2023Article
- MicroRNAs as Biomarkers for Coronary Artery Disease Related to Type 2 Diabetes Mellitus-From Pathogenesis to Potential Clinical Application.International journal of molecular sciences · 2022Review
- Downregulation of Talin-1 is associated with the increased expression of miR-182-5p and miR-9-5p in coronary artery disease.Journal of clinical laboratory analysis · 2022Article
- Genetics of macrovascular complications in type 2 diabetes.World journal of diabetes · 2021Review
- MicroRNA Sequences Modulated by Beta Cell Lipid Metabolism: Implications for Type 2 Diabetes Mellitus.Biology · 2021Review
- Epigenetics, microRNA and Metabolic Syndrome: A Comprehensive Review.International journal of molecular sciences · 2021Review
- Silencing miR-370-3p rescues funny current and sinus node function in heart failure.Scientific reports · 2020Article
- α-Tocopherol influences glycaemic control andNutrition & metabolism · 2018Article
- Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease.Biomedical reports · 2016Article
- Role of miRNAs in Epicardial Adipose Tissue in CAD Patients with T2DM.BioMed research international · 2016Article
- Epigenetics and Cardiovascular Disease in Diabetes.Current diabetes reports · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are small non coding RNAs with essential roles, of which any alteration leads to several conditions. Their roles in diabetes (DM) and its vascular complications have not been completely assessed.
aimto study the association of two miRNAs; 9 and 370, with biochemical parameters of type 2 diabetic (T2D), dyslipidemia and coronary artery disease (CAD). SUBJECTS AND
methodsBlood samples were taken from 200 subjects of both genders, in the Outpatient clinic of Al Qasr El-Einy teaching hospitals, in which levels of both miRNAs (using real time PCR) and routine parameters were measured. Subjects were divided over four groups, 50 in each group as follows; patients with T2D, patients with CAD, patients with T2D and CAD, and healthy control subjects. MAIN OUTCOME: miRNA 9 levels were expected to be over expressed in diabetic patients, while miRNA 370 levels were expected to be over expressed in those suffering from CAD and their association with CAD complication of T2D.
resultsmiRNA 9 levels were significantly higher in T2D patients and T2D patients with CAD, (1.18±0.07, and 1.31±0.08 respectively), while miRNA 370 levels were significantly higher in T2D patients, CAD patients, and T2D patients with CAD (0.59±0.05, 1.00±0.05, and 1.20±0.06 respectively), compared to control group at p = 0.000. In addition both miRNAs were still significantly associated with each other even after conducting multiple regression analysis.
conclusionThis study associates the possible role of miRNAs in the diagnosis/prognosis of CAD complication of T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.